ArticleCancer biology & medicine2025

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

Hui Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.